US PSOs Viable, Says HRET Research

3 March 1997

Some US health systems and large medical groups are well-positioned toset up Medicare provider-sponsored organizations if the Provider Sponsored Organization Act of 1997 (HR 475 and S146) is enacted, says the Hospital Research and Educational Trust. PSOs would contract directly with the federal government to provide services to Medi-care beneficiaries, bypassing insurers which, their proponents say, would raise quality and cut administrative costs.

HRET vice president for research Gloria Bazzoli says Medicare PSOs would not need some core functions for operating in the commercial market under capitation, eg plan benefit design or experience with state insurance regulations, because Med-icare would dictate the plan's design and regulations would come from federal, not state, government. Her research found that most provider organizations would be able to undertake provider relations, utilization management, actuarial assessment, claims and payment administration, management of information systems for administration and patient care functions, capital reserve management, member enrollment and tracking, and member relations. However, they have less experience in health plan marketing and negotiations with health plan purchasers.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight